Although the MSI‐H phenotype usually indicates good prognosis in early stage CRC,40 patients with MSI‐H metastatic CRC do not appear to have improved outcomes.41 In the present study, we found that novel MSI‐H‐specific mutations might contribute to the adverse impact on the outcomes of MSI‐H CRC patients through reversing the antimetastatic roles of GLTSCR1. This evidence concerns the gene BICRA and colorectal carcinoma.